Centessa Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Centessa Pharmaceuticals plc (CNTA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-235.76-151.09-216.21-381.07-10.66
Depreciation & Amortization0.940.810.130.070.00
Deferred Income Tax2.65-26.53-2.860.000.00
Stock Based Compensation33.5529.3924.9714.850.34
Change in Working Capital22.10-4.88-2.830.96-0.55
Change in Accounts Receivable-6.600.000.000.000.00
Change in Accounts Payable-4.59-2.726.353.80-0.05
Change in Other Working Capital0.060.030.17-9.83-0.50
Other Operating Activities0.0621.350.17465.420.24
Net Cash from Operating Activities-142.06-160.34-200.55-135.11-10.63
Investing Activities
Capital Expenditures-0.030.17-1.140.190.00
Acquisitions0.000.000.0063.440.00
Purchases of Investments-140.53-264.910.000.000.00
Sales/Maturities of Investments171.83-126.840.210.000.00
Other Investing Activities0.000.000.210.000.00
Net Cash from Investing Activities31.27-127.00-0.9363.260.00
Financing Activities
Debt Repayment-110.100.000.00-0.280.00
Common Stock Issued359.6120.810.72344.140.00
Other Financing Activities-5.320.00-0.26-0.300.00
Net Cash from Financing Activities364.7521.120.46660.151.36
Summary
Effect of Forex Changes on Cash1.230.62-0.421.820.00
Net Change in Cash253.96-266.23-201.02590.12-9.34
Cash at Beginning of Period128.03393.64595.086.260.00
Cash at End of Period383.22128.03393.64595.080.00
Free Cash Flow-142.09-160.51-201.68-135.30-10.63
Supplemental Disclosures
Interest Paid10.099.917.281.480.00
Income Taxes Paid0.082.941.300.000.00